Searching for novel multimodal treatments in oligometastatic pancreatic cancer.
Metastasectomy
Multimodal treatment
Oligometastatic cancer
Pancreatic cancer
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
30 Mar 2020
30 Mar 2020
Historique:
received:
28
06
2019
accepted:
05
03
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Metastatic pancreatic cancer has a median overall survival of less than 12 months, even if treated with chemotherapy. Selected patients with oligometastatic disease could benefit from multimodal treatments connecting chemotherapy and surgical treatment or radiofrequency ablation (RFA) of metastases. We present a patient with oligometastatic pancreatic cancer recurrence who was successfully treated with a multimodal therapeutic approach. A 57-year-old male initially presenting with resectable pancreatic cancer underwent pancreatoduodenectomy. The histopathological diagnosis revealed ductal pancreatic adenocarcinoma with positive surgical resection margins and negative lymph nodes. He completed six cycles of adjuvant therapy with gemcitabine (1000 mg/mq 1,8,15q 28), followed by external radiotherapy (54 Gy in 25 fractions) associated with gemcitabine 50 mg/mq twice weekly. Three years later, the patient developed multiple liver metastases, and he started FOLFIRINOX (oxaliplatin 85 mg/mq, irinotecan 180 mg/mq, leucovorin 400 mg/mq and fluorouracil 400 mg/mq given as a bolus followed by 2400 mg/mq as a 46 h continuous infusion,1q 14) as a first-line treatment. The CT scan showed a partial response after 6 cycles. After multidisciplinary discussion, the patient underwent a laparotomic metastasectomy of the three hepatic lesions. After additional postsurgical chemotherapy with 4 cycles of the FOLFIRINOX schedule, the patient remained free of recurrence for 12 months. A CT scan showed a new single liver metastasis, which was treated with radiofrequency ablation (RFA). A second radiofrequency ablation was performed when the patient developed another single liver lesion 12 months after the first RFA; currently, the patient is free from recurrence with an overall survival of 6 years from the diagnosis. Our case has benefited from successful multimodal treatment, including surgical and local ablative techniques and systemic chemotherapy. A multimodal approach may be warranted in selected patients with oligometastatic pancreatic cancer and could improve overall survival. Further research is needed to investigate this approach.
Sections du résumé
BACKGROUND
BACKGROUND
Metastatic pancreatic cancer has a median overall survival of less than 12 months, even if treated with chemotherapy. Selected patients with oligometastatic disease could benefit from multimodal treatments connecting chemotherapy and surgical treatment or radiofrequency ablation (RFA) of metastases.
CASE PRESENTATION
METHODS
We present a patient with oligometastatic pancreatic cancer recurrence who was successfully treated with a multimodal therapeutic approach. A 57-year-old male initially presenting with resectable pancreatic cancer underwent pancreatoduodenectomy. The histopathological diagnosis revealed ductal pancreatic adenocarcinoma with positive surgical resection margins and negative lymph nodes. He completed six cycles of adjuvant therapy with gemcitabine (1000 mg/mq 1,8,15q 28), followed by external radiotherapy (54 Gy in 25 fractions) associated with gemcitabine 50 mg/mq twice weekly. Three years later, the patient developed multiple liver metastases, and he started FOLFIRINOX (oxaliplatin 85 mg/mq, irinotecan 180 mg/mq, leucovorin 400 mg/mq and fluorouracil 400 mg/mq given as a bolus followed by 2400 mg/mq as a 46 h continuous infusion,1q 14) as a first-line treatment. The CT scan showed a partial response after 6 cycles. After multidisciplinary discussion, the patient underwent a laparotomic metastasectomy of the three hepatic lesions. After additional postsurgical chemotherapy with 4 cycles of the FOLFIRINOX schedule, the patient remained free of recurrence for 12 months. A CT scan showed a new single liver metastasis, which was treated with radiofrequency ablation (RFA). A second radiofrequency ablation was performed when the patient developed another single liver lesion 12 months after the first RFA; currently, the patient is free from recurrence with an overall survival of 6 years from the diagnosis.
CONCLUSIONS
CONCLUSIONS
Our case has benefited from successful multimodal treatment, including surgical and local ablative techniques and systemic chemotherapy. A multimodal approach may be warranted in selected patients with oligometastatic pancreatic cancer and could improve overall survival. Further research is needed to investigate this approach.
Identifiants
pubmed: 32228504
doi: 10.1186/s12885-020-06718-3
pii: 10.1186/s12885-020-06718-3
pmc: PMC7106565
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
271Références
Cancer Biol Ther. 2005 May;4(5):548-54
pubmed: 15846069
Arch Pathol Lab Med. 2008 Jun;132(6):931-9
pubmed: 18517275
J Gastrointest Surg. 2011 Sep;15(9):1611-7
pubmed: 21725701
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Eur J Surg Oncol. 2017 Feb;43(2):358-363
pubmed: 27856064
J Gastrointest Surg. 2009 May;13(5):915-21
pubmed: 19198960
JOP. 2010 Sep 06;11(5):434-8
pubmed: 20818110
Int J Surg. 2017 Dec;48:149-154
pubmed: 29081375
Pancreas. 1995 Nov;11(4):345-9
pubmed: 8532650
J Gastrointest Surg. 2008 Jan;12(1):86-90
pubmed: 17710505
J Natl Compr Canc Netw. 2014 Aug;12(8):1083-93
pubmed: 25099441
Surg Oncol Clin N Am. 2002 Jan;11(1):207-29, x
pubmed: 11930875
J Pancreat Cancer. 2018 Nov 01;4(1):88-94
pubmed: 30631861
BMC Cancer. 2018 Jul 28;18(1):769
pubmed: 30055578
ANZ J Surg. 2016 Dec;86(12):973-977
pubmed: 27580713